BioNTech SE · NASDAQ:BNTX
BioNTech — Q2 2026 Earnings Presentation
30 slides from BioNTech's earnings presentation, Aug 4, 2026
Slide 1: Second Quarter 2026 Financial Results & Corporate Update
Second Quarter 2026 Financial Results & Corporate Update August 4, 2026 Exhibit 99.1
Slide 2: Forward-looking statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s expected revenues and net profit/(loss) related to sales of BioNTech’s COVID-19 vaccine, refe
Slide 3: Agenda
CEO Appointment Helmut Jeggle, Supervisory Board Chairman1 2 Progress Highlights Prof. Uğur Şahin, M.D., Co-Founder & Chief Executive Officer 3 Oncology Execution Prof. Özlem Türeci, M.D., Co-Founder & Chief Medical Officer 4 Financial Performance Ramón Zapata, Chief Financial Officer
Slide 4: CEO Appointment
4 CEO Appointment Helmut Jeggle, Supervisory Board Chairman 1
Slide 5: BioNTech Appoints Guido Oelkers to Management Board as CEO
BioNTech Appoints Guido Oelkers to Management Board as CEO 5 Guido Oelkers, Ph.D. Incoming CEO ▪ Seasoned CEO and strategic leader with over 30 years of experience in the biotech and pharma industries ▪ Strong track record in transforming and scaling global organizations, driving sustainable growth
Slide 6: Progress Highlights
Progress Highlights Prof. Uğur Şahin, M.D., Co-Founder & Chief Executive Officer 2 6
Slide 7: Oncology Focus in 2026 and Progress in Q2
7 1. Partnered with Bristol Myers Squibb; 2. Partnered with DualityBio (Formerly known as BNT324/DB-1311). 1 Late-Stage Acceleration Key late-stage data readouts expected for first wave of oncology assets • Presented first global Phase 2 data for a PD-(L)1 x VEGF-A bispecific antibody in 1L NSCLC 2
Slide 8: Building a Multi-Product Company Across Tumor Focus Areas by 2030+
Building a Multi-Product Company Across Tumor Focus Areas by 2030+ Targeting 17+ Late-Stage and Pivotal Trial Readouts Informing Multiple Launch Opportunities 8 Tumor Type Incidence1 Assets Late-Stage/Pivotal Trials Expected Data Readouts2 2026 2027 2028 2029 2030+ Lung 1L NSCLC 400K Pumitamig3 ROSE
Slide 9: Oncology Execution
Oncology Execution Prof. Özlem Türeci, M.D., Co-Founder & Chief Medical Officer 3 9
Slide 10: Tumor-Focused Strategy to Address Significant Unmet Medical Needs
Tumor-Focused Strategy to Address Significant Unmet Medical Needs 10 GastrointestinalBreastLung Genitourinary Gynecologic Additional Tumors Leveraging novel combinations with next-generation IO, targeted therapies and mRNA cancer immunotherapy to maximize pipeline potential and elevate outcomes for
Slide 11: Broadening BioNTech's Coverage of Lung Cancer
1L Metastatic 2L+ Metastatic 80K 35K Resectable Stage III Unresectable 1L Metastatic 2L+ Metastatic Incidence1 220K 65K 400K 230K Broadening BioNTech’s Coverage of Lung Cancer to Maximize Pipeline Potential 11 1. Estimated 1L or adjuvant incidence (incidence + newly recurrent patients), or 2L+ drug-
Slide 12: Pumitamig + Chemotherapy Demonstrates Antitumor Activity in 1L NSCLC
Pumitamig + Chemotherapy Demonstrates Antitumor Activity Across PD-L1 Levels and Histologies in 1L NSCLC 12 Data presented at ASCO 2026. 1. Partnered with Bristol Myers Squibb. 2. 4 patients were missing central PD-L1 results and are hence excluded from this analysis. First global data for a PD-(L)1
Slide 13: Pumitamig Demonstrates Consistent Responses Between China and Global Populations
Pumitamig mono3 TPS > 1% (n=30) Pumitamig + chemo4 Overall (n=40) cORR(%) monotherapy 46.7 combination 62.5 Pumitamig + chemo5 1L TNBC (n=42) Pumitamig + chemo6 1L/2L TNBC (n=39) cORR (%) 73.8 61.5 DCR (%) 92.3 92.3 mPFS (m) 13.5 59.3% rate at 9 months Pumitamig Demonstrates Consistent Responses Bet
Slide 14: Gotistobart Has Potential to Become Chemo-Free Option in 2L SQ NSCLC
Differentiated MoA Functional Characteristics Gotistobart Has Potential to Become Chemo-Free Option in 2L SQ NSCLC 14 1. Partnered with OncoC4; 2. Balaraman, Nat Med 2026 (PRESERVE-003). Studied in several tumor types across 1000+ patients Impressive OS signals across tumor types Longer follow-up da
Slide 15: Elfetabart Drozuntecan: A Phase 3 B7-H3 Targeted ADC with Pan-Tumor Potential
B7-H3 is Overexpressed in Multiple Tumor Types Prostate NSCLC AGA- NSCLC EGFRm SCLC HR+ BC TNBC CRC Gastric Cervical Ovarian PDAC HNSCC HCC Melanoma B7H3 Expression Level 3 Development Status Ph3 Ph1/2 Ph1/2 Ph1/2 Ph2 Ph2 Ph2 Ph1/2 Ph1/2 Ph1/2 Ph2 Ph1/2 Ph1/2 Ph1/2 Elfetabart Drozuntecan: A Phase 3
Slide 16: Development Focus of mRNA Cancer Immunotherapy iNeST and FixVac Portfolios
Development Focus of mRNA Cancer Immunotherapy iNeST and FixVac Portfolios 16 Partnered with: 1. Genentech, a member of the Roche Group; 2. In collaboration with Regeneron. Autogene cevumeran1 BNT113 BNT116 Adjuvant 1L Multiple settings CRC Phase 2 PDAC Phase 2 HPV16+ PD-L1 CPS ≥1 HNSCC Phase 2/3 NS
Slide 17: Multiple Milestones Achieved in 2026 and Upcoming Catalysts
Multiple Milestones Achieved in 2026 and Upcoming Catalysts 17 Some data readouts may be event-driven and subject to change based on actual event accrual rates or publication strategy. Partnered with: 1. Bristol Myers Squibb; 2. OncoC4; 3. DualityBio; 4. MediLink; 5. Pivotal trial. 6. The timing of
Slide 18: Financial Performance
Financial Performance Ramón Zapata, Chief Financial Officer 4 18
Slide 19: Second Quarter 2026 Financial Results
Second Quarter 2026 Financial Results Lower Demand for COVID-19 Vaccines Met With Disciplined Cost Management 19 1. All numbers have been rounded and may not add up to the totals. Presentation of the unaudited interim consolidated statements of profit or loss has been condensed. 2. In addition to Bi
Slide 20: First Half 2026 Financial Results at a Glance
20 First Half 2026 Financial Results at a Glance1 Continued Focus on R&D Priority Programs Revenues € 224 million vs. €444 million in first half 2025 Adjusted R&D Expenses² € 1,004 million vs. €1,035 million in first half 2025 IFRS R&D Expenses: €1,108 million vs. €1,035 million in first half 2025 A
Slide 21: Revised Full Year 2026 Financial Guidance
Revised Full Year 2026 Financial Guidance1 21 1. Excludes risks that are not yet known and/or quantifiable and related activities. Includes effects identified from licensing arrangements, collaborations and Merger & Acquisitions (“M&A”) transactions to the extent disclosed. The guidance is based on
Slide 22: Revised Full Year 2026 Financial Guidance – Key Dynamics
Revised Full Year 2026 Financial Guidance – Key Dynamics1 22 1. Excludes risks that are not yet known and/or quantifiable and related activities. Includes effects identified from licensing arrangements, collaborations and Merger & Acquisitions (“M&A”) transactions to the extent disclosed. The guidan
Slide 23: Execution of Capital Allocation Strategy for Sustainable Value Creation
23 Concentrate investments on advancing BioNTech’s growing oncology pipeline toward commercialization, including pumitamig and ADC candidates Focusing R&D Investment Execution of Capital Allocation Strategy for Sustainable Value Creation Share Repurchase Program Started Execute up to $1.0 billion sh
Slide 24: Thank you
Thank you
Slide 25: Appendix
— Appendix BIONT=CrH
Slide 26: Reconciliation of IFRS to Adjusted Results – Q2 2026 & 2025
Reconciliation of IFRS to Adjusted Results – Q2 2026 & 2025 Financial Results In € millions except per share data1 Q2 2026 Q2 2025 IFRS Results Non-IFRS Adjustments Adjusted Results2 IFRS Results Non-IFRS Adjustments Adjusted Results2 Revenues 106 – 106 261 – 261 Cost of sales (97) – (97) (76) – (76
Slide 27: Reconciliation of IFRS to Adjusted Results – H1 2026 & 2025
Reconciliation of IFRS to Adjusted Results – H1 2026 & 2025 Financial Results In € millions except per share data1 H1 2026 H1 2025 IFRS Results Non-IFRS Adjustments Adjusted Results2 IFRS Results Non-IFRS Adjustments Adjusted Results2 Revenues 224 – 224 444 – 444 Cost of sales (168) – (168) (160) –
Slide 28: BioNTech's Oncology Pipeline
BioNTech’s Oncology Pipeline 28 Partnered with: 1. Bristol Myers Squibb; 2. Genentech, a member of the Roche Group; 3. DualityBio; 4. OncoC4; 5. MediLink; 6. Genmab; 7. In collaboration with Regeneron; 8.Trial ongoing in China only; 9.Trial is currently being conducted by or on behalf of BioNTech. B
Slide 29: BioNTech's Infectious Diseases Pipeline
29 Partnered with: 1. University of Pennsylvania; 2. Pfizer; 3. Fosun Pharma; 4. Funded by the Gates Foundation; 5. Funded by the Coalition for Epidemic Preparedness Innovations (CEPI). mRNAAntibody BioNTech’s Infectious Diseases Pipeline Phase 1 Phase 1/2 Phase 2 Commercial BNT1631 HSV BNT162 + BNT
Slide 30: Abbreviation Directory
Abbreviation Directory 30 n L nth line ELCC European Lung Cancer Congress NEN Neuroendocrine neoplasm AACR American Association for Cancer Research epi Epidemiology (sq) NSCLC (squamous) Non-small cell lung cancer ADC Antibody-drug conjugate ESMO European Society for Medical Oncology (nsq) NSCLC (no